Lexicon Pharmaceuticals (LXRX) Reports Mixed Q4 Results

Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q4 EPS of ($0.10), $0.02 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $343 thousand versus the consensus estimate of $290 thousand.

For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Hyperion DeFi (HYPD) Tops Q2 EPS by 57c
• UBS Downgrades Borouge PLC (BOROUGE:UH) to Neutral